Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase
- 1 January 2007
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 15 (1) , 312-323
- https://doi.org/10.1016/j.bmc.2006.09.057
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive HypertensionHypertension, 2005
- Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studiesAnalytical Biochemistry, 2005
- Novel mechanism of brain soluble epoxide hydrolase‐mediated blood pressure regulation in the spontaneously hypertensive ratThe FASEB Journal, 2005
- Design, Synthesis, and Biological Activity of 1,3-Disubstituted Ureas as Potent Inhibitors of the Soluble Epoxide Hydrolase of Increased Water SolubilityJournal of Medicinal Chemistry, 2004
- Structural refinement of inhibitors of urea-based soluble epoxide hydrolasesBiochemical Pharmacology, 2002
- Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic AcidsCirculation Research, 2000
- Binding of Alkylurea Inhibitors to Epoxide Hydrolase Implicates Active Site Tyrosines in Substrate ActivationJournal of Biological Chemistry, 2000
- Detoxification of environmental mutagens and carcinogens: Structure, mechanism, and evolution of liver epoxide hydrolaseProceedings of the National Academy of Sciences, 1999
- Cytochrome P450 2C is an EDHF synthase in coronary arteriesNature, 1999
- Epoxyeicosatrienoic Acids and Dihydroxyeicosatrienoic Acids Are Potent Vasodilators in the Canine Coronary MicrocirculationCirculation Research, 1998